Page last updated: 2024-10-18

dalteparin and Bone Loss, Osteoclastic

dalteparin has been researched along with Bone Loss, Osteoclastic in 1 studies

Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)

Research Excerpts

Excerpt	Relevance	Reference
"In contrast, LMWH, causes less osteopenia than heparin because it only decreases the rate of bone formation."	1.30	A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats. ( Andrew, M; Hirsh, J; Muir, JM; Shaughnessy, SG; Weitz, JI; Young, E, 1997)

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Muir, JM	1
Hirsh, J	1
Weitz, JI	1
Andrew, M	1
Young, E	1
Shaughnessy, SG	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
Effects of UFH and LMWH on Osteoprotegerin and RANKL Plasma Levels in Hemodialysis Patients[NCT00669721]				40 participants (Anticipated)	Interventional	2008-03-31	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Other Studies

1 other study available for dalteparin and Bone Loss, Osteoclastic

Article	Year
A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats. Blood, 1997, May-01, Volume: 89, Issue:9 Topics: Alkaline Phosphatase; Amino Acids; Animals; Biomarkers; Bone and Bones; Bone Development; Bone Disea	1997